Management of inflammatory bowel disease in poor responders to infliximab

References

• TerdimanJPGrussCBHeidelbaughJJAmerican Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s diseaseGastroenterology201314561459146324267474
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther201439766067124506179
   PubMed Web of Science ®Google Scholar
• ReinischWVan AsscheGBefritsRRecommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusJ Crohns Colitis20126224825822325181
   PubMed Web of Science ®Google Scholar
• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• GisbertJPGonzalez-LamaYMateJSystematic review: infliximab therapy in ulcerative colitisAliment Pharmacol Ther2007251193717229218
   PubMed Web of Science ®Google Scholar
• DignassAVan AsscheGLindsayJOThe second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current managementJ Crohns Colitis201041286221122489
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• GisbertJPPanesJLoss of response and requirement of infliximab dose intensification in Crohn’s disease: a reviewAm J Gastroenterol2009104376076719174781
   PubMed Web of Science ®Google Scholar
• SteenholdtCPalarasahYBendtzenKPre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel diseaseAliment Pharmacol Ther201337121172118323650912
   PubMed Web of Science ®Google Scholar
• SprakesMBFordACWarrenLGreerDHamlinJEfficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experienceJ Crohns Colitis20126214315322325168
   PubMed Web of Science ®Google Scholar
• De VosMLouisEJJahnsenJConsecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapyInflamm Bowel Dis201319102111211723883959
   PubMed Web of Science ®Google Scholar
• LaharieDMesliSEl HajbiFPrediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective studyAliment Pharmacol Ther201134446246921671970
   PubMed Web of Science ®Google Scholar
• MolanderPaf BjorkestenCGMustonenHFecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agentsInflamm Bowel Dis201218112011201722223566
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGReinischWReview article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-alpha therapyAliment Pharmacol Ther201134111021539588
   PubMed Web of Science ®Google Scholar
• MaserEAVillelaRSilverbergMSGreenbergGRAssociation of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s diseaseClin Gastroenterol Hepatol20064101248125416931170
   PubMed Web of Science ®Google Scholar
• SeowCHNewmanAIrwinSPSteinhartAHSilverbergMSGreenbergGRTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut2010591495419651627
   PubMed Web of Science ®Google Scholar
• CornillieFHanauerSBDiamondRHPostinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trialGut Epub1282014
   Web of Science ®Google Scholar
• O’MearaSNandaKSMossACAntibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysisInflamm Bowel Dis20142011624280879
   PubMed Web of Science ®Google Scholar
• Van AsscheGMagdelaine-BeuzelinCD’HaensGWithdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trialGastroenterology200813471861186818440315
   PubMed Web of Science ®Google Scholar
• NandaKSCheifetzASMossACImpact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-AnalysisAm J Gastroenterol20131081404723147525
   PubMed Web of Science ®Google Scholar
• GuerraIChaparroMBermejoFGisbertJPUtility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel diseaseCurr Drug Metab201112659459821495977
   PubMed Web of Science ®Google Scholar
• EserAPrimasCReinischWDrug monitoring of biologics in inflammatory bowel diseaseCurr Opin Gastroenterol201329439139623703367
   PubMed Web of Science ®Google Scholar
• Vande CasteeleNGilsASinghSAntibody response to infliximab and its impact on pharmacokinetics can be transientAm J Gastroenterol2013108696297123419382
   PubMed Web of Science ®Google Scholar
• DirksNLMeibohmBPopulation pharmacokinetics of therapeutic monoclonal antibodiesClin Pharmacokinet2010491063365920818831
   PubMed Web of Science ®Google Scholar
• FasanmadeAAAdedokunOJOlsonAStraussRDavisHMSerum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitisInt J Clin Pharmacol Ther201048529730820420786
   PubMed Web of Science ®Google Scholar
• AinsworthMABendtzenKBrynskovJTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s diseaseAm J Gastroenterol2008103494494818028512
   PubMed Web of Science ®Google Scholar
• ArijsILiKToedterGMucosal gene signatures to predict response to infliximab in patients with ulcerative colitisGut200958121612161919700435
   PubMed Web of Science ®Google Scholar
• ArijsIQuintensRVan LommelLPredictive value of epithelial gene expression profiles for response to infliximab in Crohn’s diseaseInflamm Bowel Dis201016122090209820848504
   PubMed Web of Science ®Google Scholar
• FarrellRJAlsahliMJeenYTFalchukKRPeppercornMAMichettiPIntravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trialGastroenterology2003124491792412671888
   PubMed Web of Science ®Google Scholar
• MantzarisGJViazisNPetrakiKA pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximabEur J Gastroenterol Hepatol20092191042104820139856
   PubMed Web of Science ®Google Scholar
• LofbergRLouisEVReinischWAdalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CAREInflamm Bowel Dis20121811921351211
   PubMed Web of Science ®Google Scholar
• HoGTMowatAPottsLEfficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008)Aliment Pharmacol Ther200929552753419183339
   PubMed Web of Science ®Google Scholar
• PanaccioneRLoftusEVJrBinionDEfficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trialCan J Gastroenterol201125841942521912766
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• PanaccioneRGhoshSMiddletonSCombination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146239240024512909
   PubMed Web of Science ®Google Scholar
• MackeyACGreenLLiangLCDinndorfPAviganMHepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr200744226526717255842
   PubMed Web of Science ®Google Scholar
• DeepakPStobaughDJEhrenpreisEDInfectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting SystemJ Gastrointestin Liver Dis201322326927624078983
   PubMed Web of Science ®Google Scholar
• SiegelCAFinlaysonSRSandsBETostesonANAdverse events do not outweigh benefits of combination therapy for Crohn’s disease in a decision analytic modelClin Gastroenterol Hepatol2012101465121963958
   PubMed Web of Science ®Google Scholar
• FeaganBGMcDonaldJWPanaccioneRMethotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s diseaseGastroenterology20141463e681e688
   PubMed Web of Science ®Google Scholar
• McDonaldJWTsoulisDJMacdonaldJKFeaganBGMethotrexate for induction of remission in refractory Crohn’s diseaseCochrane Database Syst Rev201212CD00345923235598
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med2004350987688514985485
   PubMed Web of Science ®Google Scholar
• RegueiroMSiemanowskiBKipKEPlevySInfliximab dose intensification in Crohn’s diseaseInflamm Bowel Dis20071391093109917480021
   PubMed Web of Science ®Google Scholar
• SchnitzlerFFidderHFerranteMLong-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohortGut200958449250018832518
   PubMed Web of Science ®Google Scholar
• HyamsJCrandallWKugathasanSInduction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in childrenGastroenterology20071323863873 quiz 1165–116617324398
   PubMed Web of Science ®Google Scholar
• ChaparroMtinez-MontielPVan DomselaarMIntensification of infliximab therapy in Crohn’s disease: efficacy and safetyJ Crohns Colitis201261626722261529
   PubMed Web of Science ®Google Scholar
• KopylovUMantzarisGJKatsanosKHThe efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximabAliment Pharmacol Ther201133334935721118397
   PubMed Web of Science ®Google Scholar
• RostholderEAhmedACheifetzASMossACOutcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisAliment Pharmacol Ther201235556256722239070
   PubMed Web of Science ®Google Scholar
• CesariniMKatsanosKPapamichaelKDose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective studyDig Liver Dis201446213513924246151
   PubMedGoogle Scholar
• SteenholdtCBrynskovJThomsenOOIndividualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trialGut201463691992723878167
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSLoftusEVJrAn open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s diseaseAm J Gastroenterol200499101984198915447761
   PubMed Web of Science ®Google Scholar
• PapadakisKAShayeOAVasiliauskasEASafety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximabAm J Gastroenterol20051001757915654784
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialAnn Intern Med20071461282983817470824
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial. GastroenterologyJanuary200713215265
   Google Scholar
• KarmirisKPaintaudGNomanMInfluence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s diseaseGastroenterology200913751628164019664627
   PubMed Web of Science ®Google Scholar
• MaCPanaccioneRHeitmanSJDevlinSMGhoshSKaplanGGSystematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximabAliment Pharmacol Ther2009301097798619681810
   PubMed Web of Science ®Google Scholar
• TaxoneraCEstellesJFernandez-BlancoIAdalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAliment Pharmacol Ther201133334034821133961
   PubMed Web of Science ®Google Scholar
• KaplanGGHurCKorzenikJSandsBEInfliximab dose escalation vs initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysisAliment Pharmacol Ther20072611–121509152017931345
   PubMed Web of Science ®Google Scholar
• LichtigerSBinionDGWolfDCThe CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapyAliment Pharmacol Ther201032101228123920955442
   PubMed Web of Science ®Google Scholar
• LouisELofbergRReinischWAdalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn’s disease: results from the CARE trialJ Crohns Colitis201371344322480772
   PubMed Web of Science ®Google Scholar
• SandbornWJAbreuMTD’HaensGCertolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximabClin Gastroenterol Hepatol20108868869520451663
   PubMed Web of Science ®Google Scholar
• BaertFDrobneDGilsAEarly trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapyClin Gastroenterol Hepatol Epub1292014
   Web of Science ®Google Scholar
• SandbornWJFeaganBGanoCSubcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology201414619610923770005
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGFedorakRNNatalizumab for the treatment of active Crohn’s disease: results of the ENCORE trialGastroenterology200713251672168317484865
   PubMed Web of Science ®Google Scholar
• YousryTAMajorEORyschkewitschCEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyN Engl J Med2006354992493316510746
   PubMed Web of Science ®Google Scholar
• LobatonTVermeireSVan AsscheGRutgeertsPReview article: anti-adhesion therapies for inflammatory bowel diseaseAliment Pharmacol Ther201439657959424479980
   PubMed Web of Science ®Google Scholar
• FeaganBGRutgeertsPSandsBEVedolizumab as induction and maintenance therapy for ulcerative colitisN Engl J Med2013369869971023964932
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• AbreuMTvon TirpitzCHardiRExtracorporeal photopheresis for the treatment of refractory Crohn’s disease: results of an open-label pilot studyInflamm Bowel Dis200915682983619130617
   PubMed Web of Science ®Google Scholar
• HommesDWDuijvesteinMZelinkovaZLong-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn’s diseaseJ Crohns Colitis20115654354922115372
   PubMed Web of Science ®Google Scholar